- Home
- EDU vs MIRM Comparison
EDU vs MIRM Comparison
Compare EDU & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDU | MIRM |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.2B |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EDU | MIRM |
|---|---|---|
| Price | $55.94 | $96.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $62.80 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 827.9K | 698.0K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $12.83 | $26.22 |
| Revenue Next Year | $11.16 | $22.04 |
| P/E Ratio | $24.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.25 | $63.23 |
| 52 Week High | $64.97 | $130.00 |
Technical Indicators
Market Signals| Indicator | EDU | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 37.65 |
| Support Level | $53.64 | $95.68 |
| Resistance Level | $57.81 | $98.03 |
| Average True Range (ATR) | 1.51 | 3.75 |
| MACD | -0.26 | -0.15 |
| Stochastic Oscillator | 61.17 | 42.38 |
Price Performance
Historical ComparisonAbout EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in livestreaming e-commerce.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.